|
KMID : 0939920030350020123
|
|
대한암학회지
2003 Volume.35 No. 2 p.123 ~ p.129
|
|
|
Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer
|
|
Kim Yong-Tai
Sohn Joo-Hyuk
Kim So-Hun
Rha Sun-Young
Kim Chul
Roh Jae-Kyung
Kim Byung-Soo
Jang Woo-Ick
Chung Hyun-Cheol
|
|
|
Abstract
|
|
|
Purpose: This study was performed to estimate the response rate and toxicity of a combination chemotherapy, which included infusional 5-Fluorouracil, Leucovorin and Docetaxel in the treatment of patients with an advanced gastric carcinoma.
Materials and Methods: Twenty two advanced gastric cancer patients, with a bidimensionally measurable or an evaluable disease, were enrolled in this study. The patients received a 5-fluorouracil 1,000 mg/m2 intravenous (IV) 24 hour infusion (Day 1∼3), leucovorin 20 mg/m2 (Day 1∼3) and docetaxel 75 mg/m2 intravenously (Day 2) every 3 weeks.
Results: The overall response rate was 45.0%. The median duration of response was 10.0 weeks (range: 4∼24), the median time to response was 8 weeks (range: 8∼20) the median time to progression was 30.0 weeks (95% CI: 16.3∼43.2) and the median overall survival duration was 36.0 weeks (95% CI: 1.7∼70.2). The median cumulative dose of 5-fluorouracil were 316.2 mg/m2/week and docetaxel was 23.9 mg/m2/week. WHO grade III, IV neutropenia, thromocytopenia and anemia occurred in 50.0%, 4.5% and 4.5% of patients, respectively. There were no occurrence of WHO grade III and IV nausea, vomiting, mucositis, conspitation, diarrhea, or neurotoxicity.
Conclusion: This chemotherapy regimen, including infusional 5-fluorouracil, leucovorin and docetaxel was an active agent against advanced gastric cancer patients, especially for previous chemotherapy naive patients. (Cancer Research and Treatment 2003;35:123-129)
|
|
|
KEYWORD
|
|
|
Stomach neoplasm, Combination Chemotherapy, Infusional 5-FU, Leucovorin, Docetaxel
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
    
|
|